April 3 (Bloomberg) -- Bayer AG’s antibiotic Avelox may shave months off the time it takes to cure tuberculosis, according to a study that could help improve treatment rates and fend off drug-resistant forms of the disease.
April 3 (Bloomberg) -- Bayer AG’s antibiotic Avelox may shave months off the time it takes to cure tuberculosis, according to a study that could help improve treatment rates and fend off drug-resistant forms of the disease.
